Sionna net loss widens 65.43% to $29.89 million in Q2 FY26
Reuters2026/08/06 11:17- Sionna Therapeutics posted a Q2 net loss of USD 29.9 million, widening from USD 18.1 million a year earlier.
- RD expense climbed to USD 21.9 million from USD 15.4 million, driven by pipeline development spending and higher personnel costs.
- GA costs rose to USD 10.6 million from USD 6.5 million, mainly on higher personnel-related expenses including stock-based compensation.
- Cash, cash equivalents and marketable securities totaled USD 268.3 million at June 30, with funding expected to last into 2028.
- PreciSION CF Phase 2a trial of SION-719 and a Phase 1 dual-combination study of SION-451 both remain on track for topline data in summer 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Mexican Peso: Support from real rates and US talks – Commerzbank
UBS Upgrades Lockheed Martin to Buy From Neutral, Adjusts Price Target to $674 From $581
The Australian dollar against the New Zealand dollar hits a 13-year high! Policy divergence between the Reserve Bank of Australia and the Reserve Bank of New Zealand intensifies, fueling interest rate differential trades.
The Australian dollar has risen to a 13-year high against the New Zealand dollar, mainly driven by the diverging interest rate outlooks of the two countries' central banks and the increase in metal prices.
ICG Infra agrees to buy UK crematoria operator Westerleigh Group from Ontario Teachers’ and USS
Crypto prices
More
